AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35773718
Drug: Standard pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacological treatments (Control group)
Trial: 34232202
Drug: Magnetic field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic field therapy (3 mT and 10 Hz) for 30 minutes daily for 11 days
Trial: 34232202
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no magnetic field therapy)
Trial: 32955839
Drug: Pelvic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic and core strength training (PCST) program, 8 weeks, twice/week
Trial: 35657948
Drug: Intramuscular depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular depot medroxyprogesterone acetate
Trial: 34394913
Drug: Bufei Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bufei Huoxue (BFHX) capsules
Trial: 32629035
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy (90.9% acyclovir, 6.2% ganciclovir, 2.9% both)
Trial: 35833805
Drug: Aflibercept monotherapy
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept monotherapy (2.0 mg intravitreous)
Trial: 35833805
Drug: Bevacizumab first
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab first (1.25 mg intravitreous)
Trial: 34528239
Drug: eltrombopag 25
RxNorm normalized name: eltrombopag 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eltrombopag 25 mg/day for 2 weeks
Trial: 34528239
Drug: eltrombopag 25
RxNorm normalized name: eltrombopag 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eltrombopag 25 mg/day
Trial: 33415861
Drug: Combined acupuncture-medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined acupuncture-medicine anesthesia
Trial: 35954713
Drug: 1% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% CHX gel
Trial: 35954713
Drug: 0.12% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% CHX solution
Trial: 33150743
Drug: Obesogenic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obesogenic medications
Trial: 35855954
Drug: sGDNF in
RxNorm normalized name: GDNF Liatermin
DrugBank: Liatermin (DB06489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sGDNF in CHB patients with fibrosis (28.4 pg/ml)
Trial: 35855954
Drug: sGDNF in
RxNorm normalized name: GDNF Liatermin
DrugBank: Liatermin (DB06489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sGDNF in CHB patients with cirrhosis (33.8 pg/ml)
Trial: 32296197
Drug: Concomitant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemoradiotherapy with temozolamide after two cycles of standard chemotherapy (Group-B)
Trial: 32608151
Drug: 755 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 755 nm picosecond Alexandrite laser treatment
Trial: 34032389
Drug: Comprehensive diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive diabetes treatment (inpatient treatment for 2 weeks)
Trial: 32822260
Drug: Sham capsule
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham capsule
Trial: 35598024
Drug: lecanemab, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lecanemab, an anti-Aβ protofibril antibody
Trial: 33514787
Drug: Fluoride-free hydroxyapatite
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride-free hydroxyapatite toothpaste (used three times daily)
Trial: 35848716
Drug: Treatment-as-usual (N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (N = 48)
Trial: 32393252
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg Q4W for 16 weeks
Trial: 36105381
Drug: BUZZY device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUZZY device with anesthetic gel
Trial: 36105381
Drug: Cold alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold alone with anesthetic gel
Trial: 32757065
Drug: Carbohydrate-protein solution
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-protein solution (CHO-P; 0.8 g carbohydrate kg BM-1 + 0.8 g protein kg BM-1)
Trial: 32757065
Drug: Carbohydrate (CHO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO; 1.6 g per kg body mass)
Trial: 32757065
Drug: Carbohydrate-protein solution
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-protein solution (CHO-P)
Trial: 34473389
Drug: Self-completed survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-completed survey measuring treatment of skin cancers
Trial: 34675131
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment
Trial: 32116211
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of non-pharmacologic and pharmacologic therapies
Trial: 34509775
Drug: Nightly medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nightly medication use with standard-dose zolpidem (QHS)
Trial: 34509775
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing with standard-dose zolpidem and placebos (IDwP)
Trial: 34509775
Drug: Continued QHS
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued QHS full dose treatment (FD/FD)
Trial: 34509775
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing with standard-dose zolpidem and placebos (FD/VD)
Trial: 34509775
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing with placebos (VD/VD)
Trial: 32108442
Drug: Sweet breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweet breakfast (30% by weight added sugar; average 32 g of sugar)
Trial: 32108442
Drug: Plain breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain breakfast (no added sugar; average 8 g of sugar)
Trial: 34698782
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-Rich Plasma (PRP) injections (n=48)
Trial: 34698782
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) injections (n=52)
Trial: 32827307
Drug: Prophylactic nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic nimodipine treatment (parenteral nimodipine from the day before surgery until the seventh postoperative day)
Trial: 35063028
Drug: Intrabronchial administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrabronchial administration of autologous adipose-derived mesenchymal stem cells (AD-MSC)
Trial: 33583208
Drug: Nurse-conducted telephone
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-conducted telephone guidance for bowel preparation before colonoscopy
Trial: 32469375
Drug: Mind Mapping
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mind Mapping (MM) group, instructed on how to construct mind maps and created weekly mind maps for 9 weeks.
Trial: 32852619
Drug: Oxygen-enriched oil-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-enriched oil-based gel dressing (G1)
Trial: 32852619
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid cream (G2)
Trial: 33454539
Drug: Tablet-computer with
RxNorm normalized name: ephedrine Oral Tablet [Primatene with ephedrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-computer with survivor stories (3 times in 12 months)
Trial: 35150025
Drug: Cumulative steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative steroid dose
Trial: 33620545
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BRJ) supplementation (140 mL, 13 mmol NO3‐)
Trial: 33538566
Drug: Novel topical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel topical cosmetic cream (NCC), applied twice daily.
Trial: 34446544
Drug: N-acetylcysteine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (150 mg/kg)
Trial: 32119035
Drug: CBD10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD10 (10 mg/kg/d)
Trial: 32119035
Drug: CBD20 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD20 (20 mg/kg/d)
Trial: 35672606
Drug: Omega-3/6 dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3/6 dietary supplement (two capsules containing 279 mg EPA, 87 mg DHA, 30 mg GLA each)
Trial: 35672606
Drug: Omega-3/6 dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3/6 dietary supplement
Trial: 34352149
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of Tenofovir Alafenamide (TAF)
Trial: 34352149
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of Tenofovir Alafenamide (TAF)
Trial: 35797913
Drug: Active iTBS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active iTBS treatment
Trial: 35797913
Drug: Sham iTBS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham iTBS treatment
Trial: 33377972
Drug: Capivasertib, 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib, 480 mg orally twice daily for 4 days on and 3 days off weekly in 28-day cycles; 400 mg if continuing hormone therapy for metastatic breast cancer.
Trial: 34588374
Drug: Royal jelly
RxNorm normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Royal jelly 690 mg daily for 4 weeks
Trial: 32707226
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids (administered post-reaction)
Trial: 35986418
Drug: Injectable buprenorphine
RxNorm normalized name: buprenorphine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable buprenorphine (BUP-XR) with adjunctive psychosocial interventions (PSI)
Trial: 35986418
Drug: Sublingual tablet
RxNorm normalized name: Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet buprenorphine (BUP-SL)
Trial: 35986418
Drug: Sublingual tablet
RxNorm normalized name: Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet buprenorphine (BUP-SL) with PSI
Trial: 35986418
Drug: Oral liquid
RxNorm normalized name: ACAI ORAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid methadone (MET) with PSI
Trial: 33605465
Drug: No antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antihypertensive treatment (Control)
Trial: 33496536
Drug: Intraoperative freehand
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative freehand bilateral ESPB with a 20-mL mixture solution of 0.25% bupivacaine and 1.0% lidocaine
Trial: 33496536
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline injection (Control)
Trial: 32687091
Drug: Intralipid (IL)
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (IL) 20% infusion at 2 ml/kg, 30 min prior to revascularization
Trial: 32687091
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received normal saline infusion
Trial: 83151875
Drug: Hepatic-Aid diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic-Aid diet (20-g Casein/30-g Hepatic-Aid per day)
Trial: 83151875
Drug: Casein diet
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein diet (50-g Casein per day)
Trial: 33548749
Drug: Deep tissue
RxNorm normalized name: Deep Tissue Percussion Therapeutic Massager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep tissue massage (DTM) applied by midwife, twice at the 10th and 22nd hour after cesarean.
Trial: 34959975
Drug: 4.0 mg
RxNorm normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg Folic Acid
Trial: 34959975
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg Folic Acid
Trial: 32601955
Drug: Multi-strain probiotic
RxNorm normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-strain probiotic capsules (Bacillus coagulans Unique IS2, Lactobacillus rhamnosus UBLR58, Bifidobacterium lactis UBBLa70, Lactobacillus plantarum UBLP40 each of 2 billion CFU; Bifidobacterium breve UBBr01, Bifidobacterium infantis UBBI01 each of 1 billion CFU) with glutamine (250 mg) taken twice a day for 28 days
Trial: 32601955
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules taken twice a day for 28 days
Trial: 34348666
Drug: LTV-h.PEEP ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTV-h.PEEP ventilation (TV of 6 ml/IBW and PEEP of 10 cm H2O)
Trial: 34348666
Drug: HTV-l.PEEP ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTV-l.PEEP ventilation (TV of 10 ml/IBW and PEEP of 4 cm H2O)
Trial: 32350847
Drug: Nanocurcumin (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocurcumin (180 mg/day)
Trial: 34957008
Drug: Camrelizumab combination
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab combination therapy
Trial: 34641706
Drug: PZL (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZL (50 μg)
Trial: 34641706
Drug: LT3 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT3 (50 μg)
Trial: 34076067
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of CBD powder
Trial: 34076067
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of CBD dissolved in corn oil
Trial: 32740218
Drug: Rivaroxaban with
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban with or without vitamin K2 or vitamin K antagonists
Trial: 32740218
Drug: Regular-dose apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regular-dose apixaban (5 mg twice daily)
Trial: 35914222
Drug: Reduced-dose apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reduced-dose apixaban (2.5 mg twice daily)
Trial: 33590823
Drug: Lemborexant (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant (5 mg and 10 mg)
Trial: 35439033
Drug: Chinese Herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese Herbal Medicine (SXC) - 3 capsules (0.5 g/capsule) taken 3 times a day for 8 weeks
Trial: 33125454
Drug: CERC‐501 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERC‐501 (10 mg/d for 6 days)
Trial: 33125454
Drug: CERC‐501 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERC‐501 (20 mg/d for 6 days)
Trial: 33125454
Drug: CERC‐501 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERC‐501 (10 mg/d for 3 days after placebo for 3 days)
Trial: 33125454
Drug: CERC‐501 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERC‐501 (20 mg/d for 3 days after placebo for 3 days)
Trial: 35420362
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg daily
Trial: 34622768
Drug: Menopur liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menopur liquid (450 IU, 600 IU/0.96 mL)
Trial: 34622768
Drug: Menopur powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menopur powder (450 IU, by 2 subcutaneous injections of 225 IU in 1 mL)
Trial: 35683351
Drug: Low-dose hzVSF-v13
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hzVSF-v13
Trial: 35683351
Drug: High-dose hzVSF-v13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hzVSF-v13
Trial: 32907828
Drug: Dual-hormone (DH)
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dual-hormone (DH) closed-loop control
Trial: 32907828
Drug: Insulin-only single-hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-only single-hormone (SH) closed-loop control
Trial: 32800913
Drug: K levels
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K levels ≥4.5 mEq/L within 36-56 hours prior to AKI diagnosis
Trial: 34931749
Drug: Berberine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine (600 mg/d)
Trial: 33206126
Drug: Tailored self-care
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored self-care intervention (home visit within 7 days of discharge and twice-monthly telephone coaching for 3 months)
Trial: 33044213
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment via ear canals
Trial: 33270989
Drug: Preoperative C-reactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative C-reactive protein (pre-CRP) ≥3.1 mg/L (high-pre-CRP)
Trial: 33270989
Drug: Postoperative maximum
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Postoperative maximum C-reactive protein (post-CRPmax) ≥77.1 mg/L (high-post-CRPmax)
Trial: 33270989
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy (ACT)
Trial: 33270989
Drug: Pre-CRP <3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-CRP <3.1 mg/L
Trial: 35811226
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrates (POC) intake in Fpo and Spo groups
Trial: 34780798
Drug: 180 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 μg/mL rhNGF eye drops, 3 times daily for 8 weeks
Trial: 34780798
Drug: 180 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 μg/mL rhNGF eye drops
Trial: 33930541
Drug: Seropositivity in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seropositivity in administration staff compared to doctors
Trial: 36462032
Drug: High-dose remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High-dose remimazolam (Group H, 0.08 mg/kg)
Trial: 36462032
Drug: Medium-dose remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Medium-dose remimazolam (Group M, 0.06 mg/kg)
Trial: 36462032
Drug: Low-dose remimazolam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remimazolam (Group L, 0.04 mg/kg)
Trial: 36462032
Drug: Medium-dose remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Medium-dose remimazolam (Group M)
Trial: 34415830
Drug: mnemoPQQ® (PQQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mnemoPQQ® (PQQ disodium salt: 21.5 mg/day)
Trial: 34349371
Drug: Laryngeal Mask
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laryngeal Mask Airway (LMA) (Group L)
Trial: 34351562
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with nano or micro zinc oxide (49, 74, 99, and 124 mg ZnO/kg diet)
Trial: 34351562
Drug: Control non-supplemented
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control non-supplemented diet (24 mg/kg)
Trial: 32847626
Drug: Prostacyclin (Iloprost)
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours
Trial: 33077817
Drug: Multimodal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal intervention (high-intensity interval aerobic fitness and strength training with nutritional supplement)
Trial: 34063673
Drug: Percutaneous neuromodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous neuromodulation (PNM) treatment